ONCAlert | 2018 ASCO Annual Meeting

CAR T-Cell Therapy for ALL

Jae Park, MD
Published Online: 12:14 AM, Tue December 9, 2014
Jae Park, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses CAR T-cell therapy for the treatment of acute lymphoblastic leukemia.

Clinical Pearls

  • Adult patients with relapsed ALL have a poor prognosis — overall survival is less than 10%.
  • This CD-19-targeted CAR modified T-cell therapy elicited an 80% complete remission rate.
  • The vast majority of these responses were MRD-negative.

<<< Go back to the ASH conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.